Nasdaq:US$15.97 (+1.13) | HKEX:HK$25.36 (+0.34) | AIM:£2.31 (-0.02)
搜索
News & Press Releases
12345678910
11
1213141516171819
找到相关结果： 945
公告及新闻稿, 新闻稿, 集团 | 2019-01-07

和黄中国医药科技将于第37届摩根大通医疗健康年会上发表演讲（只备英文版本）
Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes
阅读更多
Download Press Release (PDF)
公告及新闻稿, 监管通知 | 2018-12-31

Blocklisting Six Monthly Return
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (
阅读更多
公告及新闻稿, 监管通知 | 2018-12-31

Total Voting Rights
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-12-20

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China –  – Chi-Med to assume all development costs of life cycle indications in
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-12-20

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy
– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China
阅读更多
公告及新闻稿, 监管通知 | 2018-12-14

TR-1: Form for notification of major holdings
公告及新闻稿, 监管通知 | 2018-11-30

Total Voting Rights
London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-11-29

和黄医药就评估索凡替尼和呋喹替尼 与 PD-1 检查点抑制剂的联合疗法签订多项合作协议
2018年11月29日，星期四：和黄中国医药科技有限公司 （简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）4项合作协议，对和黄医药的索凡替尼 （surufatinib, 亦称HMPL-012或sulfatinib
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-11-26

和黄医药宣布呋喹替尼胶囊（爱优特®）首次商业上市
2018年11月26日，星期一：和黄中国医药科技有限公司（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布呋喹替尼胶囊（爱优特®）首次商业上市，并在中国开始产品销
阅读更多
下载新闻稿 (PDF)
肿瘤学 / 免疫学 | 2018-11-20

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit
Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2018-11-16

和黄医药公布呋喹替尼在中国以三线晚期非小细胞肺癌为适应症的 III期临床试验FALUCA研究结果
- 研究没有达到总生存期的主要终点，但呋喹替尼组患者无进展生存期得到延长 -   2018年11月16日，周五：和黄中国医药科技有限公司（Chi-Med（简称“和黄医药”或 “Chi-Med”）（纳斯达
阅读更多
下载通告 (PDF)
公告及新闻稿, 监管通知 | 2018-10-31

Total Voting Rights
London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac
阅读更多
公告及新闻稿, 监管通知 | 2018-10-22

Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2018-10-18

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc
阅读更多
公告及新闻稿, 监管通知 | 2018-10-05

Appointment of HSBC Bank plc as Joint Corporate Broker in London
London: Friday, October 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will co
阅读更多
公告及新闻稿, 肿瘤学 / 免疫学 | 2018-09-05

和黄医药宣布呋喹替尼胶囊在中国获批 用于治疗既往接受过其他治疗的结直肠癌患者
-呋喹替尼胶囊为转移性结直肠癌患者提供了新的口服治疗选择，将在中国市场以商品名爱优特®进行销售-   -已在JAMA发表的研究数据表明，和安慰剂相比爱优特®能够使患者总生存期得到
阅读更多
下载通告 (PDF)
公告及新闻稿, 监管通知 | 2018-08-31

Total Voting Rights
London: Friday, August 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 31, 2018, the issued share capital of Chi-Med consisted of 66,535,683 ordinary shares of US$1.00 each, wi
阅读更多
公告及新闻稿, 监管通知 | 2018-08-07

Grant of Share Options under Share Option Scheme
London: Tuesday, August 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on August 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meetin
阅读更多
公告及新闻稿, 集团 | 2018-07-27

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs
London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-07-23

和黄医药在美国启动索凡替尼以胰腺神经内分泌瘤和胆管癌为适应症的Ib/II期概念验证临床试验
2018年7月23日：和黄中国医药科技（简称“和黄医药”或 “Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布在美国启动索凡替尼以胰腺神经内分泌瘤（NET）和胆管癌（BTC）为适应症的Ib/II期
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2018-06-29

Total Voting Rights
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at June 29, 2018, the issued share capital of Chi-Med consisted of 66,532,683 ordinary shares of US$1.00 each, with e
阅读更多
公告及新闻稿, 监管通知 | 2018-06-29

Blocklisting Six Monthly Return
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2018-06-29

Chi-Med to Announce 2018 Half-Year Financial Results
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy
阅读更多
演示文稿, 科学出版物 | 2018-06-26

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
阅读更多
公告及新闻稿, 监管通知 | 2018-06-07

Grant of Share Options under Share Option Scheme
London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting i
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-06-04

和黄医药在2018年ASCO年会上公布呋喹替尼FRESCO研究更多研究数据
-继2017年ASCO年会上就FRESCO研究达到全部研究终点，呋喹替尼安全性良好，较其他靶向疗法脱靶毒性更低等数据进行口头报告后，和黄医药在2018年ASCO年会上公布了FRESCO研究进一步的研究数据-
阅读更多
下载新闻稿 (PDF)
演示文稿, 科学出版物 | 2018-06-04

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
阅读更多
演示文稿, 科学出版物 | 2018-06-04

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Presenter:     Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y
阅读更多
公告及新闻稿, 监管通知 | 2018-05-31

Total Voting Rights
London: Thursday, May 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with e
阅读更多
公告及新闻稿, 新闻稿, 集团 | 2018-05-11

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference
Press Release   London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe
阅读更多
公告及新闻稿, 监管通知 | 2018-04-30

Total Voting Rights
London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh
阅读更多
公告及新闻稿, 监管通知 | 2018-04-27

Results of AGM Meeting
London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa
阅读更多
公告及新闻稿, 监管通知 | 2018-04-23

Block Admission
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$
阅读更多
公告及新闻稿, 监管通知 | 2018-04-23

Grant of Share Options under Share Option Scheme
London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
阅读更多
演示文稿, 科学出版物 | 2018-04-17

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets
阅读更多
公告及新闻稿, 监管通知 | 2018-03-29

Total Voting Rights
London: Thursday, March 29, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 29, 2018, the issued share capital of Chi-Med consisted of 66,476,279 ordinary
阅读更多
公告及新闻稿, 监管通知 | 2018-03-28

Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 28, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2017 annual report of Chi-Med on March 26, 2018, the following awards granted under the Long Term In
阅读更多
公告及新闻稿, 集团 | 2018-03-26

2017 Annual Report and Notice of Annual General Meeting
London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
阅读更多
演示文稿, 科学出版物 | 2018-03-23

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
阅读更多
公告及新闻稿, 监管通知 | 2018-03-21

Director’s Share Dealing
London: Wednesday, March 21, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shar
阅读更多
公告及新闻稿, 监管通知 | 2018-03-20

Grant of Share Options under Share Option Scheme
London: Tuesday, March 20, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,
阅读更多
公告及新闻稿, 监管通知 | 2018-03-19

Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,
阅读更多
公告及新闻稿, 集团 | 2018-03-12

Publication of Form 20-F for the Year Ended December 31, 2017
公告及新闻稿, 集团 | 2018-03-12

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $
阅读更多
演示文稿, 科学出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-03-06

和黄医药在中国启动依吡替尼以胶质母细胞瘤为适应症的Ib/II期概念验证临床试验
2018年3月6日: 和黄医药今日宣布在中国启动依吡替尼Ib/II期概念验证临床试验，目标受试者为表皮生长因子受体（EGFR）基因扩增的胶质母细胞瘤患者。胶质母细胞瘤是脑肿瘤的一种主要类型
阅读更多
下载新闻稿 (PDF)
演示文稿, 科学出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
阅读更多
演示文稿, 科学出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
阅读更多
公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-02-13

和黄医药完成呋喹替尼以非小细胞肺癌为适应症的III期临床试验的患者入组工作，共招募527名患者
2018年2月13日：和黄医药今日宣布呋喹替尼（HMPL-013）以非小细胞肺癌为适应症的III期临床试验“FALUCA”顺利完成患者入组工作。呋喹替尼是一种高选择性强效口服血管内皮生长因子受体（VEGF
阅读更多
下载新闻稿 (PDF)
公告及新闻稿, 监管通知 | 2018-02-05

Chi-Med to Announce 2017 Final Results
London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy
阅读更多
12345678910
11
1213141516171819